-+ 0.00%
-+ 0.00%
-+ 0.00%

Yahong Pharmaceutical announced that the results of the phase Ib clinical trial of APL-1401 for the treatment of moderate to severe active ulcerative colitis were selected for the 19th European Colorectal Congress, and the clinical data of the study was published in the form of a poster.

Zhitongcaijing·12/03/2025 09:17:03
Listen to the news
Yahong Pharmaceutical announced that the results of the phase Ib clinical trial of APL-1401 for the treatment of moderate to severe active ulcerative colitis were selected for the 19th European Colorectal Congress, and the clinical data of the study was published in the form of a poster.